08:36 AM EDT, 08/04/2025 (MT Newswires) -- Praxis Precision Medicines ( PRAX ) said Monday its experimental drug vormatrigine reduced seizure frequency by a median of 56.3% in patients with focal onset seizures during an eight-week phase 2 trial.

The company said the study showed that about 22% of patients treated with the drug candidate experienced a complete seizure-free period in the final 28 days, and over 54% saw a 50% reduction in seizures within the first week.

The drug candidate was also well-tolerated with a favorable safety profile, the company said.

Shares of Praxis rose more than 14% in recent premarket activity Monday.

Price: 61.90, Change: +7.15, Percent Change: +14.44